Immune Response News and Research

RSS

Immune-related proteins are potential drug targets for gastric inflammation and cancer

A research team from South Korea studied the complex reaction of gastric inflammation induced by Helicobacter pylori (H pylori) in a systematic manner using a protein interaction network. Their study will be published on September 28, 2009 in the World Journal of Gastroenterology.

19 Oct 2009

Research study on cowpox virus

In the annals of medicine, Edward Jenner's 1796 vaccination of a young boy against smallpox, using fluid from cowpox blisters, remains a landmark case. In a new study, Kathryn Sykes, a researcher at Arizona State University's Biodesign Institute and her colleagues have taken a fresh look at cowpox.

19 Oct 2009

Research programme to develop immunological biomarkers for chronic inflammatory diseases

Persistent inflammation and the activation of the immune system is the key pathological mechanism affecting many long-term conditions, such as rheumatoid arthritis, psoriasis, ulcerative colitis, and Crohn's disease and is the predominant mechanism underlying organ transplant rejection.

19 Oct 2009

FDA approves Gardasil vaccine usage in boys and men for preventing genital warts

The U.S. Food and Drug Administration today approved use of the vaccine Gardasil for the prevention of genital warts (condyloma acuminata) due to human papillomavirus (HPV) types 6 and 11 in boys and men, ages 9 through 26.

19 Oct 2009

UT Southwestern Medical Center awarded $15.7M NIH contract to develop a new virus database

The National Institutes of Health has awarded a $15.7 million contract to UT Southwestern Medical Center and Northrop Grumman Corp. to develop an open-access national online database and analysis resource center that will help scientists study and combat viruses such as those that cause hepatitis, encephalitis, smallpox, acute respiratory distress and dengue fever, as well as newly emerging pathogenic viruses.

15 Oct 2009

Human populations may have some level of existing immunity to the pandemic H1N1 influenza, say researchers

University of California, Davis, researchers studying the 2009 H1N1 influenza virus, formerly referred to as "swine flu," have identified a group of immunologically important sites on the virus that are also present in seasonal flu viruses that have been circulating for years. These molecular sites appear to result in some level of immunity to the new virus in people who were exposed to the earlier influenza viruses.

15 Oct 2009

Interim data from Sanofi Pasteur's Influenza A 2009 Monovalent Vaccine clinical trials in infants and children

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today an interim analysis of data from clinical trials of the U.S. licensed Influenza A (H1N1) 2009 Monovalent Vaccine in infants and children 6 months through 9 years of age. The data indicate the vaccine is immunogenic and that one dose may protect many children.

15 Oct 2009

Genetic diversity thwarts the usefulness of malaria vaccine

Researchers at the University of Maryland School of Medicine Center for Vaccine Development (CVD) have charted the extreme genetic differences that occur over time in the most dangerous malaria parasite in the world. While there is no approved vaccine for malaria, various experimental vaccines are in development.

15 Oct 2009

Roche's Genome Sequencer FLX System used for critical immunogenetic study

A study published online today in the prestigious Nature Medicine journal reports that researchers at the Wisconsin National Primate Research Center have explored a new high-throughput method for decoding one of the most critical genomic regions for the immune system.

14 Oct 2009

Inovio Biomedical's proprietary DNA vaccine development platform introduced

Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today that Dr. J. Joseph Kim, president and CEO, presented at the invitation-only World Knowledge Forum being held in Seoul, South Korea.

14 Oct 2009

NanoBio to receive a $4.1M subcontract for developing nanoemulsion-based mucosal vaccine adjuvants

NanoBio Corporation today announced an award from the National Institute of Allergy and Infectious Diseases, a Division of The National Institute of Health, to fund vaccine research associated with “Innate Immune Receptors and Adjuvant Discovery.” NanoBio is the principal subcontractor for the $9.3 million contract awarded to the University of Michigan.

14 Oct 2009

Researchers find how KEAP1 tumor suppressor works

A tumor-suppressing protein snatches up an important cancer-promoting enzyme and tags it with molecules that condemn it to destruction, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports this week in the journal Molecular Cell.

12 Oct 2009

NIH to launch 2009 H1N1 influenza vaccine trials in HIV-infected pregnant women, children and youth

The first clinical trials to test whether the 2009 H1N1 influenza vaccine can safely elicit a protective immune response in pregnant women launched yesterday, and a trial to conduct the same test in HIV-infected children and youth will begin next week.

12 Oct 2009

NIH launches trial for the determination of 2009 H1N1 influenza vaccine for asthma patients

The National Institutes of Health is preparing to launch the first government-sponsored clinical trial to determine what dose of the 2009 H1N1 influenza vaccine is needed to induce a protective immune response in people with asthma, especially those with severe disease.

12 Oct 2009

World’s first engineered T cell receptor trial opens with new cellular therapy for HIV

Researchers at Adaptimmune Limited and the University of Pennsylvania School of Medicine, have announced the approval of an Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) and opening for enrolment of the first ever study using patients’ cells carrying an engineered T cell receptor to treat HIV (SL9 HA-GAG-TCR). The trial may have important implications in the development of new treatments for HIV potentially slowing – or even preventing – the onset of AIDS.

11 Oct 2009

RXi Pharmaceuticals presents new preclinical data from its advanced RNAi therapeutic platform

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced the presentation of new preclinical data from its advanced RNAi therapeutic platform at its Annual Investor Event held in New York City on Monday, October 5, 2009.

9 Oct 2009

NIAID awards $60M for research contracts to discover new adjuvants

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded six new research contracts to discover and characterize novel adjuvants, substances that can be added to vaccines to enhance the protective immune response they induce.

9 Oct 2009

Aging of the immune system coincides with higher rates of cancer in the elderly

Elderly cancer patients need a combination of treatments tailor-made to their specific needs to successfully combat the disease. The challenge is to boost their immune response to cancer vaccines, because like the rest of our organs, our immune system ages and gradually becomes less efficient as we get older.

9 Oct 2009

Destructive immune cells gain access to insulin-producing cells and help cause diabetes

St. Jude Children's Research Hospital investigators have discovered how destructive immune cells gain access to insulin-producing cells and help cause diabetes.

9 Oct 2009

Epitope spreading can get triggered by live, attenuated Listeria vaccine

Advaxis, Inc. (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) vaccine company, in collaboration with its scientific founder and Scientific Advisory Board Chair Dr. Yvonne Paterson, have shown that epitope spreading occurs in response to a form of the Company’s proprietary technology that targets tumor blood vessels (anti angiogenic antigen).

8 Oct 2009

Immune Response News and Research

Immune-related proteins are potential drug targets for gastric inflammation and cancer

Research study on cowpox virus

Research programme to develop immunological biomarkers for chronic inflammatory diseases

FDA approves Gardasil vaccine usage in boys and men for preventing genital warts

UT Southwestern Medical Center awarded $15.7M NIH contract to develop a new virus database

Human populations may have some level of existing immunity to the pandemic H1N1 influenza, say researchers

Interim data from Sanofi Pasteur's Influenza A 2009 Monovalent Vaccine clinical trials in infants and children

Genetic diversity thwarts the usefulness of malaria vaccine

Roche's Genome Sequencer FLX System used for critical immunogenetic study

Inovio Biomedical's proprietary DNA vaccine development platform introduced

NanoBio to receive a $4.1M subcontract for developing nanoemulsion-based mucosal vaccine adjuvants

Researchers find how KEAP1 tumor suppressor works

NIH to launch 2009 H1N1 influenza vaccine trials in HIV-infected pregnant women, children and youth

NIH launches trial for the determination of 2009 H1N1 influenza vaccine for asthma patients

World’s first engineered T cell receptor trial opens with new cellular therapy for HIV

RXi Pharmaceuticals presents new preclinical data from its advanced RNAi therapeutic platform

NIAID awards $60M for research contracts to discover new adjuvants

Aging of the immune system coincides with higher rates of cancer in the elderly

Destructive immune cells gain access to insulin-producing cells and help cause diabetes

Epitope spreading can get triggered by live, attenuated Listeria vaccine

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News